The 'neuroadrenergic hypothesis' in hypertension: current evidence.
about
Autonomic-Immune-Vascular Interaction: An Emerging Concept for Neurogenic HypertensionThe crystal structure of human dopamine β-hydroxylase at 2.9 Å resolutionSafety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-β-Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy SubjectsGanglionic GFAP + glial Gq-GPCR signaling enhances heart functions in vivoTherapeutic strategies for targeting excessive central sympathetic activation in human hypertensionGenes influencing circadian differences in blood pressure in hypertensive mice.No elevated plasma catecholamine levels during sleep in newly diagnosed, untreated hypertensivesAngiotensin-(1-7) in paraventricular nucleus modulates sympathetic activity and cardiac sympathetic afferent reflex in renovascular hypertensive ratsAngiotensin II and angiotensin-(1-7) in paraventricular nucleus modulate cardiac sympathetic afferent reflex in renovascular hypertensive ratsEffects on blood pressure and autonomic nervous system function of a 12-week exercise or exercise plus DASH-diet intervention in individuals with elevated blood pressure.Angiotensin II status and sympathetic activation among hypertensive patients in Uganda: a cross-sectional studyBeta-adrenergic receptor mediated inflammation control by monocytes is associated with blood pressure and risk factors for cardiovascular diseaseStress-dependent hypertension and the role of T lymphocytes.Differential TNF production by monocyte subsets under physical stress: blunted mobilization of proinflammatory monocytes in prehypertensive individuals.Neuroimmune communication in hypertension and obesity: a new therapeutic angle?Increased Sympathetic Renal Innervation in Hemodialysis Patients Is the Anatomical Substrate of Sympathetic Hyperactivity in End-Stage Renal Disease.Oxidative stress in the cardiovascular center has a pivotal role in the sympathetic activation in hypertension.Sympathetic mechanisms, organ damage, and antihypertensive treatment.Paracrine control of vascular innervation in health and disease.Nebivolol for the treatment of heart failure.Disorders of blood pressure regulation-role of catecholamine biosynthesis, release, and metabolism.Neurogenic hypertension: revelations from genome-wide gene expression profiling.Regulation of the sympathetic nervous system by nitric oxide and oxidative stress in the rostral ventrolateral medulla: 2012 Academic Conference Award from the Japanese Society of Hypertension.Adipose afferent reflex: sympathetic activation and obesity hypertension.Evidence for the role of isometric exercise training in reducing blood pressure: potential mechanisms and future directions.Autonomic nervous system dysregulation in pediatric hypertension.Arterial innervation in development and disease.Mechanisms involved in developmental programming of hypertension and renal diseases. Gender differences.Oxidative stress in the brain causes hypertension via sympathoexcitation.Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453).Angiotensin II acting on brain AT1 receptors induces adrenaline secretion and pressor responses in the rat.Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.c-Src in paraventricular nucleus modulates sympathetic activity and cardiac sympathetic afferent reflex in renovascular hypertensive rats.Brain opioid and nociceptin receptors are involved in regulation of bombesin-induced activation of central sympatho-adrenomedullary outflow in the rat.Melanocortin 3/4 receptors in paraventricular nucleus modulate sympathetic outflow and blood pressure.Artificial microRNA interference targeting AT(1a) receptors in paraventricular nucleus attenuates hypertension in rats.SOD1 gene transfer into paraventricular nucleus attenuates hypertension and sympathetic activity in spontaneously hypertensive rats.Quantity and Quality of Carbohydrate Intake during Pregnancy, Newborn Body Fatness and Cardiac Autonomic Control: Conferred Cardiovascular Risk?Short hairpin RNA interference targeting interleukin 1 receptor type I in the paraventricular nucleus attenuates hypertension in rats.Cardiac sympathetic afferent reflex response to intermedin microinjection into paraventricular nucleus is mediated by nitric oxide and γ-amino butyric acid in hypertensive rats.
P2860
Q22306336-7F169A21-F753-4DDB-B7E7-A451A2976221Q28118905-E693964A-E96C-4EB7-826D-02BBAF6FE4DBQ29999437-5AA15026-FC00-4B5A-9788-F04FC3FEB3BAQ30354373-E57BA6A8-CEA4-4E4D-87BC-B08A912B2276Q33805761-2729D76E-B2A4-4F3B-B65D-6DF8472B99ECQ33889435-87CFEBA8-B4AE-413F-808D-CBF483A00ADCQ33939221-73AAF05F-17D6-4D18-BEDC-14382979F0C4Q34472153-B8CB7AF0-BB44-411E-B4BE-B567919D9D9CQ34534106-7A92B1CF-DF53-495E-8C74-FAC76478EB3AQ35341894-A1DF676E-4F8E-4EBC-BE40-ABF57D2E7174Q35815199-ACAC4C1C-2082-466F-A091-8B4EDCAD9B90Q36244806-F46BF937-8AA4-47CF-9600-34CC64E61BE9Q36303921-C787870F-B5A2-4A62-85AC-88E63C706040Q36456727-7E6C3404-B6A7-4DA5-8DF2-6015D1AC51C0Q36824063-F988DDEB-7804-4C09-8E64-A81BE2855161Q36836484-AFB0C9BD-0D19-45B0-8D87-91784FF75287Q37846532-442082B0-A322-4C00-A243-D26D47AD5948Q37859637-DCA0739B-26C1-4614-B2A2-7DE010ED7BA7Q37892042-BC2ED05E-71B4-4EA3-96B0-240C4029DED6Q37943377-96AE06DF-8057-45B1-BBCF-A24149605B73Q37954116-82F0E257-51B5-4175-8687-A241BABD4051Q38013692-50E733A8-A919-45A6-B9B8-F58F421A8A23Q38122303-42CBAF22-CA36-45F7-A607-A39FFECAF253Q38151943-88570549-5CB9-4FB4-8DB2-F7B4562FE861Q38156714-15D8563F-AD51-4957-9915-97250B3A78D5Q38196354-DF5B5AAB-F74F-40F8-8245-435405AAEFEEQ38245885-51FC0054-3ED4-43D4-94CC-81D83E541FFEQ38267484-78BCE9DA-C029-4073-9141-44489BE368F1Q41943162-D3355510-6436-430E-A322-D1DED8C884DBQ42159015-18AE7903-0EF3-4047-8AD3-0A9EA030ACD5Q42292543-C2FA8D60-D979-4480-A17A-CBFBCEDABE37Q42476216-81874415-B31C-4EB3-9350-B3222E4DD8A7Q42749550-61B0C9E4-A053-4A91-9C5A-F4646865870FQ44332515-8C952929-D661-4B21-BD5C-6568B5D6F116Q44523641-05A30F52-2B4D-4504-954B-BEB79C34A20AQ45873654-64427A83-4AA4-47D4-80A6-D89B705543F6Q46514659-FD59E1D7-E096-4F84-891F-7E3C9B59B3CDQ47160543-F91BE598-0F8A-4864-9905-2D5E87C9D468Q47396920-E1362555-733E-4686-BE54-E2B5FE1B047DQ47865079-CA51B7C7-6863-4DF6-A1EC-215760CCB73C
P2860
The 'neuroadrenergic hypothesis' in hypertension: current evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The 'neuroadrenergic hypothesis' in hypertension: current evidence.
@en
The 'neuroadrenergic hypothesis' in hypertension: current evidence.
@nl
type
label
The 'neuroadrenergic hypothesis' in hypertension: current evidence.
@en
The 'neuroadrenergic hypothesis' in hypertension: current evidence.
@nl
prefLabel
The 'neuroadrenergic hypothesis' in hypertension: current evidence.
@en
The 'neuroadrenergic hypothesis' in hypertension: current evidence.
@nl
P2860
P1476
The 'neuroadrenergic hypothesis' in hypertension: current evidence
@en
P2093
Fosca Quarti-Trevano
Guido Grassi
P2860
P304
P356
10.1113/EXPPHYSIOL.2009.047381
P577
2009-12-11T00:00:00Z